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Abstract
Background: HPV has been found repeatedly in esophageal carcinoma tissues. However, reported detection rates
of HPV DNA in these tumors have varied markedly. Differences in detection methods, sample types, and
geographic regions of sample origin have been suggested as potential causes of this discrepancy.
Methods: HPV L1 DNA and HPV genotypes were evaluated in 435 esophageal carcinoma specimens collected
from four geographic regions with different ethnicities including Anyang in north China, Shantou in south China,
Xinjiang in west China, and the United States. The HPV L1 fragment was detected using SPF1/GP6+ primers. HPV
genotyping was performed using genotype specific PCR.
Results: Two hundred and forty four of 435 samples (56.1%) tested positive for HPV L1. Significant differences in
detection rate were observed neither among the three areas of China nor between China and the US. HPV6, 16,
18, 26, 45, 56, 57, and 58 were identified in L1 positive samples. HPV16 and 57 were the most common types in all
regions, followed by HPV26 and HPV18.
Conclusions: HPV infection is common in esophageal carcinoma independent of region and ethnic group of
origin. Findings in this study raise the possibility that HPV is involved in esophageal carcinogenesis. Further
investigation with a larger sample size over broader geographic areas may be warranted.
Background
Esophageal carcinoma is a common malignancy and its
mortality rate is among the highest for cancers overall
[1]. There is extreme geographic variation in the inci-
dence of esophageal carcinoma, with differences of as
much as 300-fold between areas of greatest and least
prevalence within a given country, or between one
country and another [2]. Substantial alcohol use com-
bined with smoking has been found to greatly increase
the risk of esophageal cancer in western countries [3,4].
In contrast, vitamin deficient diets and food containing
potential carcinogens have been suggested to be signifi-
cant risk factors for esophageal cancer in China and
other central Asian countries [5-9]. However, the asso-
ciation between esophageal cancer and these identified
risk factors is generally weak for the high risk popula-
tion of China, implying that the major etiology remains
to be determined [10,11].
In 1982, Syrjanen found that HPV infection caused
pathological lesions in esophageal cancer specimens
[12]. Since then many studies which have used a variety
of techniques have evaluated the association between
HPV and risk of esophageal cancer. However, the results
of these studies have been inconsistent, and it has been
suggested that this inconsistency may result in part
from geographic variation in esophageal cancer preva-
lence. Most studies that have failed to detect HPV DNA
in esophageal tumors were conducted in low-risk areas
such as the USA or Europe [13,14]. Studies in high-risk
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HPV in esophageal cancer [15-18].
In this study, we evaluated tissues from 435 esopha-
geal cancers collected from four different regions with
multiple ethnicities including Han, Kazakh, American
Japanese, American Caucasian, and African American
for HPV DNA. We found comparable rates of HPV
detection and similar HPV genotypes in the esophageal
cancer samples from all of these geographic areas.
Methods
Subjects
A total of 435 esophageal cancer samples collected in an
unselected manner were used in this study. Of these,
166 were from Anyang, a city in northern China, 103
w e r ef r o mS h a n t o u ,ac i t yi ns o u t h e r nC h i n a ,7 8w e r e
from Xinjiang, an autonomous region in western China,
and 88 were from the United States (US). Among the
study subjects, 61.9% were Han, the majority ethnic
group of China, 17.9% were Kazakh, a minority group of
Chinese living in western China with a high prevalence
of esophageal cancer, 9.4% were Caucasian, 9.0% were
Japanese, and 1.8% were African-American. The male to
female ratio was 2.4:1 (Table 1). The tumor samples
included 34 esophageal adenocarcinomas (all from the
United States), and 401 esophageal squamous cell carci-
nomas. The carcinoma tissue specimens were collected
from non-necrotic areas of tumor immediately following
esophagectomy, and samples were stored at -70°C for
subsequent processing. In every case the pathological
diagnoses were rendered by local pathologists. Demo-
graphic and medical information including age, gender,
race, tumor site, tumor stage, family history, and history
of smoking and drinking were obtained from patient
medical records. Informed consent was obtained from
all participants. Institutional review board approval was
obtained from all participating institutions.
Quality control
DNA preparation, PCR setup, and PCR product detec-
tion were carried out in separated spaces with speci-
mens moving through the laboratory in one direction
only. Environmental contamination was monitored con-
sistently before experiments, and decontamination was
carried out on a regular basis. To monitor potential
contamination during DNA preparation, one mouse
liver tissue sample was inserted after each batch of 16
esophageal cancer tissues and processed with these can-
cer tissues. The human globin gene and HPV L1 were
tested in these controls to confirm absence of contami-
nation during DNA preparation.
In each 96-well PCR reaction plate the following con-
trols were included: four mouse liver DNA samples pro-
cessed together with the human cancer specimens as a
DNA preparation control; three controls without a DNA
template; two sets of HPV16 plasmid DNA, each con-
taining 100, 10, 1 and 0.1 copies admixed with 100 ng
of human genome DNA; and one positive control con-
taining 100 ng of ESCC (esophageal squamous cell car-
cinoma) DNA mixed together from several tumors,
which had previously tested positive for HPV L1.
Assay results were interpreted and used for this study
only when controls met the following criteria: 1. all
seven negative controls were negative; 2. ESCC DNA
was positive; and 3. at least one set of plasmid controls
was positive and the intensity of the positive signal cor-
responded with the input copy number. In cases where
any negative control was positive, testing was repeated.
DNA preparation
DNA from 88 US samples was extracted in the NCI
laboratory (Maryland, USA) using the FlexiGene kit
(Qiagen, Valencia, CA). DNA from all other samples
was prepared using the H.Q. & Q. Tissue DNA Kit (U-
GENE BIOTECHNOLOGY CO., LTD, Anhui, China).
DNA was diluted to 35 ng/μl, and 3 μl (~100 ng) of
DNA was used for each of the various PCR analyses.
HPV L1 detection
A set of primers, SPF1/GP6+, which amplify an L1 frag-
ment of approximately 184 bp were used. These primer
sets were reported previously to be highly sensitive [19].
The polymerase chain reaction was carried out under
the following conditions. Qiagen Hot Start Taq DNA
polymerase mixture was used with 2 mM MgCl2,a n d
16 pmol of each primer. Enzyme activation was carried
out at 95°C for 15 minutes, followed by 45 amplification
cycles at 95°C for 40 seconds, 49°C for 50 seconds, 72°C
for 30 seconds, and a final extension at 72°C for 5
minutes.
HPV genotype determination and detection
To determine the HPV genotypes in samples for each
region from different geographic areas, L1 positive sam-
ples were mixed in equal molar ratios for each region
and cloned into a TA vector. Forty-eight colonies from
each batched cloning were sequenced.
Type-specific detection of HPV was performed with
type-specific PCR primers (Table 2) for genotypes
detected from batched cloning. PCR was performed at
95°C for 15 minutes, followed by 40 amplification cycles
at 95°C for 40 seconds, 57°C for 40 seconds, 72°C for 40
seconds, and a final extension at 72°C for 5 minutes.
Sequencing analysis
PCR products were purified using a PCR clean-up gel
extraction column (MACHEREY-NAGEL GmbH & Co,
Düren, Germany) according to the manufacturer’s
instructions and were directly sequenced using a capil-
lary sequencer (ABI Prism 3100).
Statistical analysis
Univariate comparisons of rates were performed using
the chi-square test. Unconditional multivariate logistic
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type infections and HPV detection rates among different
regions adjusting for potential confounders. All statisti-
cal analysis was done using SAS 9.1.3. P values of less
than 0.05 were considered to be statistically significant.
Results
Overall HPV prevalence according to region
Of 435 of esophageal cancer samples, 244 (56.1%) were
HPV L1 positive. Stratifying by region, HPV L1 was
detected in 86 (51.8%) of the Anyang samples, 62
(60.2%) of the Shantou samples, 42 (53.8%) of the Xin-
jiang samples, and 54 (61.4%) of the US samples. There
were no significant differences among the detection
rates in the samples from the three areas of China (P =
0.131) (Table 3). In addition, in comparing samples
from China (54.8%) and the US (61.4%), no significant
difference was observed (P = 0.522) (Table 3).
Type specific HPV prevalence according to region and
epidemiological characteristics
Using the batched cloning method, a total of eight geno-
types including HPV6, 16, 18, 26, 45, 56, 57, and 58
were found. Type-specific primer (Table 2) derived PCR
w a st h e nc a r r i e do u to nL 1p o s i t i v es a m p l e s .T h em o s t
prevalent genotype was HPV16 which was detected in
96 (49.2%) of the China samples, of which 29 were from
Anyang, 48 were from Shantou, 19 were from Xinjiang,
and in 39 (58.2%) of the US samples. The difference of
detection rate of HPV16 between China and US was sta-
tistically significant (P = 0.003). HPV57 was the second
Table 1 Demographic characteristics and TNM stage of subjects by region and HPV infection status
Region HPV infection status
China US
P†
Total (N = 435)
P†† Variables Anyang
N = 166
No.(%)
Shantou
N = 103
No.(%)
Xinjiang
N=7 8
No.(%)
Total
N = 347
No.(%)
N=8 8
No.(%)
HPV(-)
No.(%)
HPV(+)
No.(%)
Age ≤60 87(52.4) 74(71.8) 62(79.5) 223(64.3) 39(44.3) 0.001 121(63.4) 141(57.8) 0.239
>60 79(47.6) 29(28.2) 16(20.5) 124(35.7) 49(55.7) 70(36.6) 103(42.2)
Gender Female 55(33.1) 34(33.0) 27(34.6) 116(33.4) 12(13.6) <0.001 63(33.0) 65(26.6) 0.150
Male 111(66.9) 69(67.0) 51(65.4) 231(66.6) 76(86.4) 128(67.0) 179(73.4)
Tobacco‡ Never 83(50.6) 54(52.4) 59(75.6) 196(56.8) 19(22.1) <0.001 104(55.3) 111(45.7) 0.047
Ever 81(49.4) 49(47.6) 19(24.4) 149(43.2) 67(77.9) 84(44.7) 132(54.3)
Alcohol‡‡ Never 118(72.0) 91(88.3) 65(83.3) 274(79.4) 20(24.4) <0.001 143(76.5) 151(62.9) 0.003
Ever 46(28.0) 12(11.7) 13(16.7) 71(20.6) 62(75.6) 44(23.5) 89(37.1)
Race Han 166(100.0) 103(100.0) - 269(77.5) - - 121(63.4) 148(60.7) 0.257
Kazakh - - 78(100.0) 78(22.5) - 36(18.8) 42(17.2)
Caucasion - - - - 41(46.6) 18(9.4) 23(9.4)
Black - - - - 8(9.1) 5(2.6) 3(1.2)
Japanese - - - - 39(44.3) 11(5.8) 28(11.5)
Anatomic location* Upper third 20(18.3) - 1(1.6) - - - 14(17.9) 7(7.5) 0.115
Middle third 71(65.1) - 33(53.2) - - 45(57.7) 59(63.4)
Lower third 18(16.5) - 28(45.2) - - 19(24.4) 27(29.0)
TNM stage I 7(4.2) 21(20.4) 0(0.0) 28(8.1) 31(35.2) <0.001 20(10.5) 39(16.0) 0.204
IIa 84(50.6) 26(25.2) 34(43.6) 144(41.5) 28(31.8) 77(40.3) 95(38.9)
IIb 35(21.1) 37(36.0) 34(43.6) 106(30.5) 12(13.7) 59(30.9) 59(24.2)
III 40(24.1) 19(18.4) 10(12.8) 69(19.9) 17(19.3) 35(18.3) 51(20.9)
†P values for the differences between China and US were calculated with the Pearson Chi-square test.
††P values for the differences between HPV(+) and HPV(-) groups were calculated with the Pearson Chi-square test.
‡Tobacco was classified as any record of use (ever) or no record of use (never). Information on tobacco was missing in four cases.
‡‡Alchol was classified as any record of use (ever) or no record of use (never). Information on tobacco was missing in eight cases.
*Part of the data was not available, and statistic analyses were based on available data.
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of the China samples, of which 27 were from Anyang, 8
were from Shantou, 11 were from Xinjiang, and in 14
(20.9%) of the US samples. In addition, HPV26 was also
common both in China and US with a prevalence of
9.2% in China and 13.4% in the US. HPV18 was found
in three of the four study areas with a detection rate of
14.5% in Anyang, 8.1% in Shantou, and 7.5% in the US.
HPV6, 45, 56, and 58 were much less common. Three
cases (4.0%) from Anyang were HPV45 positive. Nine
(20.0%) and 4 (8.9%) cases from Xinjiang were HPV6
and HPV56 positive respectively (Table 4). And all these
differences were not reaching the significant standard.
In addition, we further compared the detection rates of
each genotype by epidemiological characteristics, includ-
ing age, gender, smoking and alcohol use. However, no
statistical differences were found (data not shown).
Among L1 positive samples, 43 (17.6%) were co-
infected with more than one HPV type. Multiple HPV
genotypes were found in 30 (15.8%) cases from China,
of which 9 were from Anyang, 15 were from Shantou, 6
were from Xinjiang, and in 13 cases (24.1%) from the
US among the L1 positive samples. In addition, no sig-
nificant differences in multiple infection rates were
observed among three areas of China (P = 0.963) or
between China and the US (P = 0.834).
Table 2 HPV type-specific primers and sizes of PCR-amplified fragments†
HPV type Primer direction†† Primer sequence Gene Size of PCR fragment (bp)
6F 5 ’-CTGTTTCGAGGCGGCTATC-3’ E6 323
R5 ’-TGGAGGTTGCAGGTCTAAT-3’
16 F 5’-ATGACTTTGCTTTTCGGGATTTAT-3’ E6E7 335
R5 ’-GCATGATTACAGCTGGGTTTCTC-3’
18 F 5’-AACCGAGCACGACAGGAACG-3’ E7 368
R5 ’-GGATGCACACCACGGACACA-3’
26 F 5’-TGACCTACGCTGCTACGAACAA-3’ E7 294
R5 ’-CCCGCCCCTCCTCATTT-3’
45 F 5’-ACGACCCTACAAGCTACCAGATTT-3’ E6 454
R5 ’-TTGCTATACTTGTGTTTCCCTACG-3’
56 F 5’-TGGGGTGCTGGAGACAAACA-3’ E7 271
R5 ’-CTGCACCACAAACTTACACTCACA-3’
57 F 5’-ATACCCGAAATTGTTGACCT-3’ E7 182
R5 ’-TGCTCCAGATGCCTTATGT-3’
58 F 5’-CCAGGACGCAGAGGAGAAACC-3’ E6 387
R5 ’-CGACCCGAAATATTATGAAACCTT-3’
†PCR: abbreviation for polymerase chain reaction.
††F, forward; R, reverse.
Table 3 HPV detection rate and multiple infection rate by region*
HPV L1(+)
Region Unclassified
No. (%)
Single
infection
No. (%)
Multiple
infection
No. (%)
P Total
No. (%)
HPV L1
(-)
No. (%)
P
Anyang (N = 166) 20(23.3) 57(66.3) 9(10.5) 0.963† 86(51.8) 80(48.2) 0.131‡
Shantou (N = 103) 4(6.5) 43(69.4) 15(24.2) 62(60.2) 41(39.8)
Xinjiang (N = 78) 6(14.3) 30(71.4) 6(14.3) 42(53.8) 36(46.2)
China (N = 347) 30(15.8) 130(68.4) 30(15.8) 0.834†† 190(54.8) 157(45.2) 0.522‡‡
US (N = 88) 1(1.9) 40(74.1) 13(24.1) 54(61.4) 34(38.6)
Total (N = 435) 31(12.7) 170(69.7) 43(17.6) 244(56.1) 191(43.9)
*Multiple infection was determined by type specific E6 or E7 PCR.
†P value for the rates of multiple type infections among three areas of China was calculated by unconditional logistic regression adjusted for age, gender,
tobacco, alcohol and pathological stage.
††P value for the rates of multiple type infections between China and US was calculated by unconditional logistic regression adjusted for age, gender, tobacco,
alcohol and pathological stage.
‡P value for HPV detection rates among three areas of China was calculated by unconditional logistic regression adjusted for age, gender, tobacco, alcohol and
pathological stage.
‡‡P value for HPV detection rates between China and US was calculated by unconditional logistic regression adjusted for age, gender, tobacco, alcohol and
pathological stage.
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HPV infection in esophageal adenocarcinomas and
squamous cell carcinomas was compared among the
samples from the US. L1 was detected in 18 (52.9%) of
esophageal adenocarcinomas and 36 (66.7%) of esopha-
geal squamous cell carcinomas (P = 0.200). The detec-
tion rates in these 2 types of carcinomas therefore
showed no statistically significant difference. Tumor site
data was available only for squamous cell carcinomas
from the Anyang and Xinjiang regions, and evaluation
of the association between anatomic location and HPV
prevalence was carried out in these cases. L1 was
detected in 7 (33.3%) of carcinomas located in the upper
third of esophagus, 59 (56.7%) in the middle third and
27 (58.7%) in the lower third. No statistically significant
relationship between HPV infection and tumor site was
found in this study (P = 0.115).
Impact of potential risk factors on HPV prevalence
HPV infection was further analyzed on the basis of sev-
eral potential risk factors (Table 5). However, the L1
positive rate did not show any statistically significant
association with sex, age, race, or TNM stage. In con-
trast, HPV positivity was associated with alcohol use
(OR = 1.69, 95% CI = 1.01-2.83). Samples were stratified
into cases from China and from the US, and upon repe-
tition of the above analysis, identical results were
observed in the Chinese cases. However, HPV positives
were not linked with alcohol use in the US samples
(data not shown).
Discussion
Over the past twenty years, many reports regarding
HPV infection in esophageal cancer have been pub-
lished, and the reported HPV detection rate in these
tumors has ranged from 0 to 67% [15,17,20-23]. To
explain these marked differences in the reported detec-
tion rate, sampling methods, demographic and ethnic
factors, disease status, and sensitivity of detection
methods have been cited as potential causes of inconsis-
tency. HPV was detected infrequently in esophageal car-
cinomas collected from western countries, whereas it
was more frequently detected in esophageal cancers
from regions of high HPV incidence, particularly in
China and South Africa. It therefore has been proposed
that HPV infection may play a role in esophageal carci-
nogenesis only in high incidence regions [24,25]. In con-
trast to previous reports, our results demonstrated the
prevalence of HPV infection in esophageal cancer is
independent of geographic area and ethnicity, suggesting
HPV infection is commonly associated with esophageal
cancer and raising the possibility that it may play a role
in the etiology of esophageal carcinoma.
The differences in prevalence of HPV in esophageal
carcinoma in this study and previous reported preva-
lence may have resulted in part from use of different
analytic strategies. We recently demonstrated two ways
in which HPV infection in the esophagus differs from
the infection observed in cancers of the uterine cervix
(data not shown). First, real time PCR revealed that the
HPV load in esophageal specimens was at least two
orders of magnitude lower than that in cervical cancer.
In addition, HPV genotypes found in esophageal speci-
mens were different from those found in cervical can-
cers. Based on these observations, we proposed in a
previous study that the low HPV copy number might
therefore result in a falsely low detection rate in esopha-
geal cancer. To provide evidence for this line of reason-
ing, a series of HPV 16 positive cervical cancer
specimens were employed to test a mimic esophageal
cancer model. The copy number of HPV/cell in these
cervical cancers was first determined using real time
PCR. The samples were then diluted to 0.1-0.01/cell
which was similar to the average copy number in eso-
phageal cancers and tested for L1. Of 24 diluted sam-
ples, 6 were negative in the first round of PCR. An
additional round of PCR was carried out, and all six
Table 4 Type-specific HPV infection distribution by region
China
HPV type Total
No. (%)
Anyang
No. (%)
Shantou
No. (%)
Xinjiang
No. (%)
Total
No. (%)
US
No. (%)
P*
HPV-6 9(3.4) 0 (0.0) 0 (0.0) 9(20.0) 9(4.6) 0 (0.0) 0.268
HPV-16 135(51.5) 29(38.1) 48(64.9) 19(42.2) 96(49.2) 39(58.2) 0.003
HPV-18 22(8.4) 11(14.5) 6(8.1) 0 (0.0) 17(8.7) 5(7.5) 0.979
HPV-26 27(10.3) 6(7.9) 10(13.5) 2(4.4) 18(9.2) 9(13.4) 0.080
HPV-45 3(1.1) 3(4.0) 0 (0.0) 0 (0.0) 3(1.5) 0 (0.0) 1.000
HPV-56 4(1.5) 0 (0.0) 0 (0.0) 4(8.9) 4(2.1) 0 (0.0) 0.587
HPV-57 60(22.9) 27(35.5) 8(10.8) 11(24.4) 46(23.6) 14(20.9) 0.519
HPV-58 2(0.8) 0 (0.0) 2(2.7) 0 (0.0) 2(1.0) 0 (0.0) 1.000
Total 262(100.0) 76(100.0) 74(100.0) 45(100.0) 195(100.0) 67(100.0)
*P values for type-specific HPV detection rates according to region in which subject live were calculated with the Pearson Chi-square test or Fisher’s exact test.
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were positive, indicating that repeat testing may
decrease the false negative rate in samples with low
HPV copy numbers. On this basis, an analytic strategy
for HPV detection in esophageal cancers was
formulated.
Briefly, L1 detection was performed twice in each eso-
phageal sample. L1 positivity in either test was counted
as positive for calculation of the detection rate. A
batched TA cloning assay was used to evaluate the HPV
genotypes in the sample population. Utilizing this
approach, HPV57 which is not common in cervical can-
cers was identifiable in esophageal specimens. Genotype
specific E6 or E7 PCR was performed to determine the
genotypes in L1 positives.
It is of interest to note that HPV57 presented as the
second most common genotype and accounted for
22.9% of L1 positive esophageal cancer tissues from all
four areas under investigation. HPV57 was originally
identified in benign, premalignant, and malignant lesions
of the nasal cavity [26]. The signature pattern of HPV57
E6 and E7 oncogenes was closely related to HPV16 and
18 oncogenes. NIH 3T3 cells expressing HPV57 exhib-
ited morphological transformation indicating that the
activity of HPV57 in vitro is comparable to other high-
risk HPV types [27]. The role of HPV57 in esophageal
carcinogenesis thus warrants further investigation.
The associations between HPV infection and age, gen-
der, tumor TNM stage, tobacco smoking and alcohol
use were analyzed. Of these factors only alcohol use was
associated with HPV positive esophageal cancers as
compared with HPV negative subjects. However, there
was no statistical evidence of such relationship when the
analysis was limited to US samples only, but the possibi-
lity that the limited US sample size might have contrib-
uted to this result cannot be excluded. Alternatively, as
samples from the US included both esophageal squa-
mous cell carcinomas and adenocarcinomas, it is possi-
ble that these two types of cancers may arise from
different carcinogenic pathways and thus confound the
data. As such, further investigation with a larger sample
size should be carried out to further evaluate the effect
of alcohol use on HPV infection in the esophagus.
We recognize that there are several limitations in this
study, one of which is selection bias. As a hospital-based
study, these cancer patients were all recruited from local
hospitals and as a result the population from which we
obtained these samples cannot be precisely defined.
Patient self selection of a hospital for treatment may
have also introduced selection bias. These factors may
limit the sample’s representativeness and capacity for
inference. Another limitation is that some crucial infor-
mation which would potentially allow broader conclu-
sions was not obtained for this study (for example,
anatomic location of the tumor in the US samples). In
this study we demonstrated for the first time that HPV
DNA is both relatively common in esophageal cancer,
and is independent of geographic region and ethnicity of
Table 5 Risk of esophageal cancer associated with HPV infection according to gender, age, tobacco and alcohol use,
and tumor stage
HPV(-)
No.(%)
HPV(+)
No.(%)
Unadjusted
OR (95% CI)
Adjusted
OR (95% CI)*
Age ≤60 121(63.4) 141(57.8) 1.00 1.00
> 60 70(36.6) 103(42.2) 1.26 (0.86-1.86) 1.17 (0.78-1.75)
Gender Female 63(33.0) 65(26.6) 1.00 1.00
Male 128(67.0) 179(73.4) 1.36 (0.90-2.05) 1.06 (0.64-1.75)
Tobacco† No 104(55.3) 111(45.7) 1.00 1.00
Yes 84(44.7) 132(54.3) 1.47‡ (1.00-2.16) 1.08 (0.64-1.80)
Alcohol†† No 143(76.5) 151(62.9) 1.00 1.00
Yes 44(23.5) 89(37.1) 1.92‡‡ (1.25-2.94) 1.69‡ (1.01-2.83)
TNM stage I 20(10.5) 39(16.0) 1.00 1.00
IIa 77(40.3) 95(38.9) 0.63 (0.34-1.17) 0.68 (0.36-1.28)
IIb 59(30.9) 59(24.2) 0.51 (0.27-0.98) 0.58 (0.30-1.14)
III 35(18.3) 51(20.9) 0.75 (0.38-1.49) 0.74 (0.36-1.50)
*Age, gender, smoking, tobacco use, alcohol use and TNM stage were included in the multivariate logistic regression model.
†Information on tobacco was missing in four cases.
††Information on alcohol was missing in eight cases.
‡P<0.05.
‡‡P<0.01.
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independent of all previously identified risk factors for
esophageal cancer except alcohol use.
Conclusions
This observed consistency of the prevalence of HPV
infection in esophageal carcinoma from different geo-
graphic areas may warrant further investigation with lar-
ger numbers of subjects over additional areas. However,
the findings here serve to raise the possibility that HPV
plays a role in the etiology of esophageal carcinoma.
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